Process for the manufacturing of betamimetics

Abstract
The present invention relates to a process for preparing betamimetics of formula 1,
Description

The present invention relates to a process for preparing betamimetics of formula 1,




embedded image



wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R2 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R3 denotes hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, O—C1-4-alkylene-COO—C1-4-alkyl.


BACKGROUND TO THE INVENTION

Betamimetics (β-adrenergic substances) are known from the prior art. For example reference may be made in this respect to the disclosure of U.S. Pat. No. 4,460,581, which proposes betamimetics for the treatment of a range of diseases.


For drug treatment of diseases it is often desirable to prepare medicaments with a longer duration of activity. As a rule, this ensures that the concentration of the active substance in the body needed to achieve the therapeutic effect is guaranteed for a longer period without the need to re-administer the drug at frequent intervals. Moreover, giving an active substance at longer time intervals contributes to the well-being of the patient to a high degree. It is particularly desirable to prepare a pharmaceutical composition which can be used therapeutically by administration once a day (single dose). The use of a drug once a day has the advantage that the patient can become accustomed relatively quickly to regularly taking the drug at certain times of the day.


The aim of the present invention is therefore to provide a method of producing betamimetics which on the one hand confer a therapeutic benefit in the treatment of COPD or asthma and are also characterised by a longer duration of activity and can thus be used to prepare pharmaceutical compositions with a longer duration of activity. A particular aim of the invention is to prepare betamimetics which, by virtue of their long-lasting effect, can be used to prepare a drug for administration once a day for treating COPD or asthma. A further objective of the invention, apart from those mentioned above, is to prepare betamimetics which are not only exceptionally potent but are also characterised by a high degree of selectivity with respect to the β2-adrenoceptor.







DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a process for preparing a compound of formula 1,




embedded image



wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R2 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R3 denotes hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, O—C1-4-alkylene-COO—C1-4-alkyl,


    characterised in that a compound of formula 1a,




embedded image



wherein PG represents a protective group, is reacted with a compound of formula 1b,




embedded image



wherein R1, R2, R3 and n have the meaning given above, in an organic solvent to yield a compound of formula 1c,




embedded image



wherein R1, R2, R3, n and PG have the meanings given above, and the compound of formula 1 is obtained therefrom by cleaving the protective group PG.


The above process is preferably used to prepare compounds of formula 1, wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen, halogen or C1-4-alkyl;
  • R2 denotes hydrogen, halogen or C1-4-alkyl;
  • R3 denotes hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH or O—C1-4-alkylene-COO—C1-4-alkyl.


The above process is preferably used to prepare compounds of formula 1, wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen, fluorine, chlorine, methyl or ethyl;
  • R2 denotes hydrogen, fluorine, chlorine, methyl or ethyl;
  • R3 denotes hydrogen, C1-4-alkyl, OH, fluorine, chlorine, bromine, O—C1-4-alkyl, O—C1-4-alkylene-COOH, O—C1-4-alkylene-COO—C1-4-alkyl.


The above process is preferably used to prepare compounds of formula 1, wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen, methyl or ethyl;
  • R2 denotes hydrogen, methyl or ethyl;
  • R3 denotes hydrogen, methyl, ethyl, OH, methoxy, ethoxy, O—CH2—COOH, O—CH2—COO-methyl or O—CH2—COO-ethyl.


The above process is preferably used to prepare compounds of formula 1, wherein

  • n denotes 1 or 2;
  • R1 denotes hydrogen or methyl;
  • R2 denotes hydrogen or methyl;
  • R3 denotes hydrogen, methyl, OH, methoxy, O—CH2—COOH or O—CH2—COO-ethyl.


In the process according to the invention a compound of formula 1a is reacted with a compound of formula 1b in a suitable solvent. Suitable solvents which may be used are organic solvents, while particularly preferred solvents are selected from among tetrahydro-furan, toluene, ethanol, n-propanol, n-butanol, n-butylacetate, dimethylformamide, methoxyethanol, ethyleneglycol and dioxane. According to the invention particularly preferred solvents are n-propanol, tetrahydrofuran and dioxane, while dioxane and n-propanol are of particular importance.


Based on the compound 1a used it is preferable according to the invention to use at least stoichiometric amounts of compound 1b. Compound 1b may optionally also be used in excess, for example in amounts of up to 3 equivalents, preferably up to 2.5 equivalents, particularly preferably about 1 to 2, optionally 1 to 1.5 equivalents based on the compound 1a used.


The reaction is preferably carried out at elevated temperature, preferably at a temperature above 40° C., particularly preferably at a temperature above 50° C. Particularly preferably, the reaction mixture is heated to the boiling temperature of the solvent used.


At this temperature the reaction is then carried out over a period of about 1 to 72 hours, preferably 10 to 60 hours, particularly preferably 20 to 50 hours.


Once the reaction has ended the solvent is eliminated and the residue remaining is taken up in an organic polar solvent, preferably a C1-8-alcohol or C3-8-ester, particularly preferably in ethanol or ethyl acetate, and filtered. The filtrate is acidified, preferably with an inorganic acid, particularly preferably with hydrochloric acid and after a period of about 10 minutes to 12 hours, preferably 20 minutes to 6 hours, particularly preferably 30 minutes to 3 hours, the product is filtered off.


The protective group PG is preferably cleaved from compounds of formula 1a by hydrogenation in a suitable solvent. Examples of suitable solvents include organic solvents, preferably organic, polar solvents, particularly preferred solvents are selected from among tetrahydrofuran, various C3-8-esters and C1-8-alcohols. Preferably, according to the invention, the solvents used are tetrahydrofuran, ethanol and methanol, while ethanol and methanol are of particular significance.


The hydrogenation in the process according to the invention preferably uses catalysts in the presence of hydrogen. Preferred catalysts are suitable transition metal catalysts, preferably heterogeneous transition metal catalysts, particularly preferably palladium-containing catalysts, particularly a palladium-charcoal mixture.


The hydrogenation is preferably carried out in the presence of an excess of hydrogen. The latter is provided according to the invention by a hydrogen pressure of 1 bar to 10 bar, preferably between 2 and 7 bar, particularly preferably between 2.5 and 4.5 bar.


Preferably the hydrogenation is carried out at elevated temperature, preferably from 25 to 70° C., particularly preferably from 30 to 60° C., particularly from 35 to 50° C. After the reaction has ended the catalyst is removed, preferably by filtration.


Then the solvent is eliminated and the product is recrystallised from a suitable organic solvent, preferably a C1-8-alcohol or a mixture of C1-8-alcohols, particularly preferably from a mixture of methanol and an alcohol selected from among i-propanol, n-propanol and ethanol.


In a preferred process according to the invention the compound of formula 1a is prepared by reacting a compound of formula 2a,




embedded image



wherein PG has the meaning given in claim 1 and R4 denotes halogen, preferably bromine or chlorine.


In the process according to the invention a compound of formula 2a is reacted in a suitable solvent with DIP chloride (diisopinocampheylchloroborane). Suitable solvents are preferably organic solvents. Preferred solvents are selected from among diethyl ether, tert-butyl-methylether 2-methyltetrahydrofuran, tetrahydrofuran, toluene and dioxane. Particularly preferably according to the invention the solvents used are tert-butyl-methylether, tetrahydrofuran and dioxane, of which dioxane and tetrahydrofuran are of particular importance.


The DIP chloride may be used in pure form or in the form of a solution, preferably in an inert organic solvent, particularly preferably an aliphatic solvent, particularly pentane, hexane, heptane or octane.


The DIP chloride is added at reduced temperature in the reaction medium, the temperature preferably being below 0° C., particularly preferably below −10° C.; more particularly the addition is carried out at −20 to −40° C.


The DIP chloride is added over a period of 10 min to 6 hours, preferably 30 min to 4 hours, particularly preferably 1 to 3 hours. In particular, the addition takes place over a period of 70 to 110 min.


Based on the compound 2a used, according to the invention at least stoichiometric amounts of DIP chloride are preferably used. The DIP chloride may optionally also be used in excess, for example in amounts of up to 3 equivalents, preferably 2.5 equivalents, particularly preferably 1.5 to 2.5 equivalents based on the compound 2a used.


After the DIP chloride has been added the reaction mixture is stirred over a period of 10 min to 4 hours, preferably 30 min to 3 hours, particularly preferably 40 to 80 min; in particular, the reaction mixture is stirred for another 50 to 70 min after the addition has ended. During this time the reaction mixture is adjusted to a temperature of −20 to 20° C., particularly preferably from −10 to 10° C., particularly from −5 to 5° C.


Once the desired temperature has been reached, an at least stoichiometric amount of sodium hydroxide (NaOH), dissolved in water, is added, based on the amount of DIP chloride used. If desired the NaOH may also be used in excess, for example in amounts of up to 3 equivalents, preferably in amounts of up to 2.5 equivalents, particularly preferably 1.5 to 2.5 equivalents, based on the amount of DIP chloride used. Preferably a pH value of 12 to 14, particularly preferably 12.5 to 13.5, particularly 12.7 to 13.3 is measured in the reaction mixture after the addition of NaOH has ended.


After the desired pH has been selected, the reaction mixture is stirred over a period of 10 min to 4 hours, preferably 30 min to 3 hours, particularly preferably 40-80 min, and in particular the reaction mixture is stirred for a further 50-70 min During this time the reaction mixture is adjusted to a temperature of 0 to 40° C., particularly preferably from 10 to 30° C., particularly from 15 to 25° C. Then the reaction mixture is adjusted to a pH of 7 to 10, particularly preferably 8 to 9, particularly 8.2 to 8.8, with an acid, preferably an inorganic acid, particularly preferably hydrochloric acid.


Finally, the product can be isolated from the reaction mixture by extraction with an organic solvent and obtained as a solid by precipitation with another suitable organic solvent.


In a preferred process according to the invention the compound of formula 2a is prepared by reacting a compound of formula 3a,




embedded image



wherein PG has the meaning given in claim 1.


In the process according to the invention a compound of formula 3a is reacted with a halogenating reagent in a suitable solvent. Examples of suitable solvents are organic solvents. Preferred solvents are selected from among acetic acid, butyl acetate, methylene chloride, tetrahydrofuran, toluene and dioxane. Particularly preferred solvents according to the invention are tetrahydrofuran and dioxane.


In a preferred embodiment of the invention the halogenating reagent used is a brominating reagent, particularly preferably bromine, N-bromosuccinimide, benzyltrimethylammonium tribromide and tetrabutylammonium tribromide. Based on the compound 3a used, preferably at least stoichiometric amounts of halogenating reagent are used according to the invention. If required the halogenating reagent may also be used in excess, for example in amounts of up to 3 equivalents, preferably in amounts of up to 2 equivalents, particularly preferably 1 to 1.5 equivalents, based on the compound 3a used. The halogenating reagent may be added to the reaction mixture in a solvent, preferably in an organic, polar solvent, particularly preferably in methanol, ethanol and dioxane, particularly in methanol and dioxane, or in a mixture thereof, particularly in a mixture of methanol and dioxane.


The reaction is preferably carried out at a temperature of 0 to 40° C., preferably at a temperature of 10 to 30° C., particularly preferably at a temperature of 15 to 25° C.


After the halogenating reagent has been added the reaction mixture is stirred for a period of 10 min to 6 hours, preferably 30 min to 4 hours, particularly preferably 90 to 150 min.


To isolate the product water is added to the reaction mixture, wherein the mixture is cooled to a temperature of −10° C. to 10° C., preferably 0 to 10° C., particularly preferably 0 to 5° C. and stirred for a period of 10 min to 4 hours, preferably 30 min to 2 hours, particularly preferably 50 to 70 min, after the addition of the water. The product may be obtained after filtration or centrifugation and drying.


In a preferred process according to the invention the compound of formula 3a is prepared by reacting a compound of formula 4a,




embedded image



wherein PG has the meaning given in claim 1.


In the process according to the invention a compound of formula 4a is hydrogenated in a suitable solvent. Examples of suitable solvents are organic solvents, preferably organic, polar solvents. Particularly preferred solvents are selected from among dimethylformamide, N-methylpyrrolidinone, tetrahydrofuran, 2-methyltetrahydrofuran, toluene and dioxane. According to the invention the following are particularly preferred as solvents: dimethylformamide, tetrahydrofuran, 2-methyltetrahydrofuran and dioxane, wherein dimethylformamide and 2-methyltetrahydrofuran are of particular importance.


The hydrogenation in the process according to the invention preferably uses catalysts in the presence of hydrogen. Preferred catalysts are suitable transition metal catalysts, preferably heterogeneous transition metal catalysts, particularly preferably nickel- or platinum-containing catalysts, particularly platinum oxide.


The hydrogenation is preferably carried out in the presence of an excess of hydrogen. The latter is provided according to the invention by a hydrogen pressure of 1 bar to 10 bar, preferably from 2 to 7 bar, particularly preferably from 2.5 to 4.5 bar.


Preferably the hydrogenation is carried out at a temperature from 0 to 50° C., particularly preferably from 10 to 40° C., particularly from 20 to 30° C. After the reaction has ended the catalyst is removed from the liquid phase, preferably by filtration.


The intermediate product 4a# in the solution,




embedded image



wherein PG has the meaning given in claim 1, may be isolated or further reacted directly to form a compound of formula 3a.


In accordance with the process of the invention a base, preferably a weak base, particularly preferably a carbonate, particularly potassium carbonate, is taken and the compound of formula 4a# is added in pure form or in a solution, particularly in the form of the solution filtered off from the hydrogenation catalyst in the preceding step.


Based on the compound 4a used, preferably at least twice the stoichiometric amount of the base is used according to the invention. The base may optionally also be used in excess, for example in amounts of up to 6 equivalents, preferably in amounts of up to 4 equivalents, particularly preferably about 3 to 3.5 equivalents, based on the compound 4a used.


Then chloroacetyl chloride is added to the reaction mixture. The chloroacetyl chloride is added over a period of 10 min to 2 hours, preferably 15 min to 1 hour, particularly preferably 25 to 35 min.


Based on the compound 4a used, preferably at least stoichiometric amounts of the chloroacetyl chloride are used according to the invention. If required, the chloroacetyl chloride may also be used in excess, for example in amounts of up to 4 equivalents, preferably in amounts of up to 3 equivalents, particularly preferably about 1.5 to 2 equivalents, based on the compound 4a used.


After the chloroacetyl chloride has been added the reaction mixture is stirred for a period of 10 min to 6 hours, preferably 1 to 4 hours, particularly preferably 140 to 160 min.


The reaction is preferably carried out at elevated temperature, preferably at a temperature of above 40° C., particularly preferably at a temperature of above 50° C., particularly preferably from 60° C. to 70° C.


The reaction is ended by the addition of water. The compound of formula 3a can be purified and isolated by extraction of the reaction mixture with water and subsequent recrystallisation from a suitable organic solvent. For the crystallisation it is preferable to use an aliphatic hydrocarbon, particularly preferably an aliphatic cyclic hydrocarbon, particularly cyclohexane and methylcyclohexane.


In a preferred process according to the invention, the compound of formula 4a is prepared by reacting a compound of formula 5a,




embedded image



wherein PG has the meaning given in claim 1.


In the process according to the invention a compound of formula 5a is reacted with a nitrogenating reagent in a suitable solvent. Suitable solvents include organic solvents and acids, preferably organic protic solvents and acids. Particularly preferred solvents are acetic acid and sulphuric acid, particularly acetic acid.


For the nitrogenation in the process according to the invention it is preferable to use 6-65% nitric acid, as well as nitronium tetrafluoroborate or acetyl nitrate. Nitric acid, particularly 65% nitric acid, is particularly preferred.


Based on the compound 5a used, preferably at least stoichiometric amounts of the nitrogenating reagent are used according to the invention. If required the nitrogenating reagent may also be used in excess, for example in amounts of up to 2 equivalents, preferably in amounts of up to 1.5 equivalents, particularly preferably about 1 to 1.1 equivalents, based on the compound 5a used.


After the nitrogenating reagent has been added the reaction mixture is stirred over a period of 10 min to 4 hours, preferably 20 min to 3 hours, particularly preferably 40 to 80 minutes.


Then the reaction mixture is diluted with sufficient water to precipitate the compound of formula 4a from the solution. To complete the crystallisation stirring is continued for a further 20 min to 3 hours, preferably 30 min to 2 hours, particularly preferably 40-80 min, at a temperature of 0° C. to 20° C., preferably at 5° C. to 15° C., particularly preferably at 8° C. to 12° C. The compound of formula 4a may be obtained by separation from the liquid phase, preferably by filtration or centrifugation.


In a preferred process according to the invention, the compound of formula 5a is prepared by reacting a compound of formula 6a,




embedded image


In the process according to the invention a compound of formula 6a is reacted in a suitable solvent with a protective group PG-A, wherein A denotes a suitable leaving group such as for example chlorine, bromine, iodine, methanesulphonyl, trifluoromethanesulphonyl or p-toluenesulphonyl. Preferably, a protective group is used which can be eliminated as described with reference to the cleaving of the protective group PG from compounds of formula 1a. Particularly preferably, an optionally substituted benzyl protective group is used.


In a preferred process according to the invention, the compound of formula 1b is prepared by reacting a compound of formula 2b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5 and

  • R5 denotes Me.


In the process according to the invention a compound of formula 2b is reacted with a strong base in a suitable solvent. Examples of suitable solvents include organic solvents; particularly preferred solvents are selected from among ethanol, 2-ethoxyethanol and ethyleneglycol or mixtures thereof. Particularly preferably, 2-ethoxyethanol or ethyleneglycol or a mixture thereof is used as the solvent according to the invention. Preferably, the mixture consists of equal parts by volume of 2-ethoxyethanol and ethyleneglycol, although a slight excess of one or other solvent is also possible.


The strong base used is particularly an inorganic hydroxide, preferably an alkaline earth or alkali metal hydroxide, particularly sodium hydroxide or potassium hydroxide. According to the invention potassium hydroxide is of particular importance.


Based on the compound 2b used, preferably at least stoichiometric amounts of the strong base are used according to the invention. If required the strong base may also be used in excess, for example in amounts of up to 8 equivalents, preferably in amounts of up to 6 equivalents, preferably about 2 to 4, particularly preferably 3.5 to 4.5 equivalents, based on the compound 2b used.


The reaction is preferably carried out at elevated temperature, preferably at a temperature of above 100° C., particularly preferably at a temperature of above 120° C. Particularly preferably the reaction mixture is heated to 140-160° C., particularly to 145-155° C.


Then for extraction the reaction mixture is diluted with a solvent and water. Solvents of particular interest are toluene, xylene, heptane, methylcyclohexane or tert-butyl-methylether, preferably toluene or xylene. The aqueous phase is eliminated, the organic phase is extracted with water in additional purification steps. The water may be acidic, neutral or alkaline, by the use of common additives. Preferably the organic phase is extracted once with acidified water and then with basic water. The product may be obtained from the organic phase by elimination of the solvent.


In a preferred process according to the invention, the compound of formula 2b is prepared by reacting a compound of formula 3b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5.


In the process according to the invention a compound of formula 3b is reacted in a suitable solvent with acetonitrile in the presence of an acid. Examples of suitable solvents are acids, preferably organic acids, while the particularly preferred solvent is acetic acid.


Based on the compound 3b used, preferably at least stoichiometric amounts of acetonitrile are used according to the invention. Preferably the acetonitrile is used in excess, for example in amounts of up to 6 equivalents, preferably in amounts of up to 5 equivalents, particularly preferably about 2 to 4 equivalents, particularly 2.5 to 3.5 equivalents, based on the compound 3b used.


The acid in whose presence the reaction is carried out is preferably sulphuric acid, formic acid, p-toluenesulphonic acid, methanesulphonic acid, perchloric acid or polyphosphoric acid, particularly preferably sulphuric acid.


Based on the compound 3b used, preferably at least stoichiometric amounts of the acid are used according to the invention. If required the acid may also be used in excess, for example in amounts of up to 2 equivalents, preferably in amounts of up to 1.5 equivalents, particularly preferably about 1 to 1.1 equivalents, based on the compound 5a used. After the acid has been added the reaction mixture is stirred for a period of 1 to 5 hours, preferably 2 to 4 hours, particularly preferably 170 to 190 min.


The reaction is preferably carried out at elevated temperature, preferably at a temperature of above 30° C., particularly preferably at a temperature of above 40° C., particularly preferably from 45° C. to 60° C. Surprisingly, it has been found that in this process no undesirable cleaving of the methyl ether function takes place as might have been expected from the literature (Can. J. Chem. 56 (1978), 3054-3058).


Then the reaction mixture is transferred into a second reactor which contains a cooled mixture of solvents. Examples of suitable solvents include mixtures of polar and non-polar solvents, preferably aqueous, organic, polar and non-polar solvents. Particularly preferred solvents as components of the mixture are selected from among water, tert-butyl-methylether, tetrahydrofuran, toluene, dioxane, hexane, cyclohexane and methylcyclohexane. According to the invention it is particularly preferable to use, as ingredients of the mixture, water, tert-butylmethylether, tetrahydrofuran, toluene, cyclohexane and methylcyclohexane, while a mixture of water, tert-butylmethylether and methylcyclohexane is of particular importance.


Preferably the mixture of solvents is kept at a reduced temperature, preferably at a temperature of below 20° C., particularly preferably at a temperature below 15° C., particularly preferably 0° C. to 15° C.


In order to precipitate the product out of the solvent, the pH of the reaction mixture is raised, preferably into the basic range, particularly preferably from pH 8 to 12, particularly from pH 9 to 10. Preferably an ammonia solution is used to raise the pH value.


After the addition has ended and the pH has been adjusted the reaction mixture is stirred for a period of 10 min to 3 hours, preferably 20 min to 2 hours, particularly preferably 50 to 70 min.


Then the product is removed by centrifuging and washed with the above-mentioned solvents used for the reaction. A product of greater purity can be obtained by further recrystallisation, or precipitation, e.g. with C1-8-alcohols and water.


In a preferred process according to the invention, the compound of formula 3b is prepared by reacting a compound of formula 4b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5.


In the process according to the invention a compound of formula 4b is subjected to a Grignard reaction in a suitable solvent with methylmagnesium bromide. Organic solvents are suitable for use as the solvent. Preferred solvents are selected from among diethyl ether, tert-butyl-methylether, tetrahydrofuran, toluene and dioxane. According to the invention it is particularly preferable to use tert-butyl-methylether, tetrahydrofuran and toluene as solvent.


The reaction is preferably carried out at ambient temperature, preferably at a temperature of 10 to 20° C., particularly preferably at a temperature of 15 to 25° C.


After the educts have been combined the reaction mixture is stirred for a period of 10 min to 3 hours, preferably 20 min to 2 hours, particularly preferably 50 to 70 min.


To stop the reaction, water and an acid, preferably sulphuric acid, are added to the reaction mixture. After extraction of the organic phase using standard methods the product may be isolated by elimination of the solvent. The purity of the product can be increased by recrystallisation from an organic non-polar solvent, preferably n-heptane.


The invention further relates to the new intermediate products of formula 3a,




embedded image



wherein PG has the meaning given in claim 1.


The invention further relates to the new intermediate products of formula 4a,




embedded image



wherein PG has the meaning given in claim 1.


The invention further relates to the new intermediate products of formula 4a#,




embedded image



wherein PG has the meaning given in claim 1.


The invention further relates to the new intermediate products of formula 2b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5 and

  • R5 denotes Me.


The subject matter of the invention also includes a process for preparing compounds of formula 2a,




embedded image



wherein PG has the meaning given in claim 1 and R4 denotes halogen, preferably bromine or chlorine, characterised in that a compound of formula 3a,




embedded image



wherein PG has the meaning given in claim 1, is reacted with the halogenating reagent selected from among tetrabutylammonium tribromide, benzyltrimethylammonium dichloriodide, N-bromo-succinimide, N-chloro-succinimide, sulphuryl chloride and bromine/dioxane, preferably tetrabutylammonium tribromide or N-bromo-succinimide.


The subject matter of the invention also includes a process for preparing compounds of formula 3a,




embedded image



wherein PG has the meaning given in claim 1, characterised in that a compound of formula 4a,




embedded image



wherein PG has the meaning given in claim 1, is subjected to catalytic hydrogenation and then reacted with chloroacetyl chloride.


The subject matter of the invention also includes a process according to claim 16, wherein a compound of formula 4a#,




embedded image



wherein PG has the meaning given in claim 1, is formed as the intermediate product of the hydrogenation.


The subject matter of the invention also includes a process for preparing compounds of formula 4a,




embedded image



wherein PG has the meaning given in claim 1 and is characterised in that a compound of formula 5a,




embedded image



wherein PG has the meaning given in claim 1, is reacted with a nitrogenating reagent selected from among 65% nitric acid, potassium nitrate/sulphuric acid or nitronium tetrafluoroborate, preferably 65% nitric acid.


The subject matter of the invention also includes a process for preparing compounds of formula 1b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5, characterised in that a compound of formula 2b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5 and

  • R5 denotes Me,
  • is reacted with a base selected from among potassium hydroxide, sodium hydroxide, lithium hydroxide and caesium hydroxide, preferably potassium hydroxide or sodium hydroxide.


The subject matter of the invention also includes a process for preparing compounds of formula 2b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5 and

  • R5 denotes Me,
  • characterised in that a compound of formula 3b,




embedded image



wherein R1, R2, R3 and n have the meanings given in claims 1 to 5, is reacted with a compound of formula




embedded image



wherein R5 has the meaning given above, in the presence of a hygroscopic reagent selected from among sulphuric acid, formic acid, p-toluenesulphonic acid, methanesulphonic acid, perchloric acid and polyphosphoric acid, preferably sulphuric acid, and is then reacted with a base selected from among aqueous solutions of ammonia, sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate.


Terms And Definitions Used


By an “organic solvent” is meant, within the scope of the invention, an organic, low-molecular substance which can dissolve other organic substances by a physical method. To be suitable the prerequisite for the solvent is that neither the dissolving substance nor the dissolved substance should be chemically altered during the dissolving process, i.e. the components of the solution should be recoverable in their original form by physical separation processes such as distillation, crystallisation, sublimation, evaporation or adsorption. For various reasons, not only the pure solvents but also mixtures that combine the dissolving properties may be used. Examples include:

    • alcohols, preferably methanol, ethanol, propanol, butanol, octanol, cyclohexanol;
    • glycols, preferably ethyleneglycol, diethyleneglycol;
    • ethers/glycolethers, preferably diethyl ether, tert-butyl-methylether, dibutylether, anisol, dioxane, tetrahydrofuran, mono-, di-, tri-, polyethyleneglycol ethers;
    • ketones, preferably acetone, butanone, cyclohexanone;
    • esters, preferably acetic acid esters, glycolesters;
    • amides and other nitrogen compounds, preferably dimethylformamide, pyridine, N-methylpyrrolidone, acetonitrile;
    • sulphur compounds, preferably carbon disulphide, dimethylsulphoxide, sulpholane;
    • nitro compounds, preferably nitrobenzene;
    • halogenated hydrocarbons, preferably dichloromethane, chloroform, tetrachlormethane, tri- and tetrachloroethene, 1,2-dichloroethane, chlorofluorocarbons;
    • aliphatic or alicyclic hydrocarbons, preferably benzines, petroleum ether, cyclohexane, methylcyclohexane, decaline, terpene-L.; or
    • aromatic hydrocarbons, preferably benzene, toluene, o-xylene, m-xylene, p-xylene;


      or corresponding mixtures thereof.


By the term “C1-4-alkyl” (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 4 carbon atoms. Examples include: methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or tert-butyl. In some cases the abbreviations Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, etc. are also used for the above-mentioned groups. Unless stated otherwise, the definitions propyl and butyl include all the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec-butyl and tert-butyl etc.


By the term “C1-4-alkylene” (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms. Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene or 1,2-dimethylethylene. Unless stated otherwise, the definitions propylene and butylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example, propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene.


By the term “C1-8-alcohol” are meant branched and unbranched alcohols with 1 to 8 carbon atoms and one or two hydroxy groups. Alcohols with 1 to 4 carbon atoms are preferred. Examples include: methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, sec-butanol or tert-butanol. In some cases the abbreviations MeOH, EtOH, n-PrOH, i-PrOH, n-BuOH, i-BuOH, t-BuOH, etc. are optionally also used for the above-mentioned molecules. Unless stated otherwise, the definitions propanol, butanol, pentanol and hexanol include all the possible isomeric forms of the groups in question. Thus for example propanol includes n-propanol and iso-propanol, butanol includes iso-butanol, sec-butanol and tert-butanol etc.


By the term “C3-8-esters” are meant branched and unbranched esters with a total of 3 to 8 carbon atoms. Esters of acetic acid with 3 to 6 carbon atoms are preferred. Examples include: methyl acetate, ethyl acetate, n-propyl acetate, i-propyl acetate or n-butyl acetate, of which ethyl acetate is preferred.


“Halogen” within the scope of the present invention denotes fluorine, chlorine, bromine or iodine. Unless stated to the contrary, fluorine, chlorine and bromine are regarded as preferred halogens.


“Protective groups” for the purposes of the present invention is a collective term for organic groups with which certain functional groups of a molecule containing a number of active centres can temporarily be protected from attack by reagents so that reactions take place only at the desired (unprotected) sites. The protective groups should be introduced selectively under mild conditions. They must be stable for the duration of the protection under all the conditions of the reactions and purifying procedures which are to be carried out; racemisations and epimerisations must be suppressed. Protective groups should be capable of being cleaved again under mild conditions selectively and ideally in high yields. The choice of a suitable protective group, the reaction conditions (solvent, temperature, duration, etc.), and also the options for removing a protective group are known in the art (e.g. Philip Kocienski, Protecting Groups, 3rd ed. 2004, THIEME, Stuttgart, ISBN: 3131370033). Preferred protective groups are optionally substituted benzyl, diphenylmethyl, trityl, tosyl, mesyl or triflate, of which optionally substituted benzyl is particularly preferred.


EXPERIMENTAL SECTION



embedded image



wherein Bn denotes benzyl and

  • n may denote 1 or 2;
  • R1 may denote hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R2 may denote hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl;
  • R3 may denote hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, O—C1-4-alkylene-COO—C1-4-alkyl.


8-[(1R)-1-hydroxy-2-[[2-aryl-1,1-dimethyl-ethyl]-amino]ethyl]-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one-hydrochloride of formula 1c: 7.00 kg (23.54 mol) 8-(2R)-oxiranyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 1a and 34.70 mol aryl-1,1-dimethyl-ethylamine of formula 1b are placed in 70 l 1,4-dioxane. The reactor contents are heated to 97° C. and stirred for 48 hours at this temperature. Then the mixture is cooled to 40° C. and 56 l of 1,4-dioxane are distilled off in vacuo. 70 l ethanol are added to the residue, it is cooled to 25° C., and 4.15 kg (34.14 mol) hydrochloric acid (30%) are added at 25° C. within 15 minutes. Then the mixture is inoculated and stirred until crystallisation occurs. The resulting suspension is cooled to 20° C. and stirred for a further 2 hours. The product is centrifuged, washed with 21 l of ethanol and dried in vacuo at 50° C.


Yield (1c): 84-90%, enantiomer purity according to HPLC: 89.5-99.5%.


6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-aryl-1,1-dimethyl-ethyl]-amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one-hydrochloride of formula 1: 19.49 mol of 8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethyl-ethyl]-amino]ethyl]-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one-hydrochloride of formula 1c are placed in the hydrogenation reactor and suspended with 40 l methanol. 500 g palladium on charcoal 10% (50% water) are suspended in 17 l methanol and added to the hydrogenation reactor. The mixture is hydrogenated at 40° C. internal temperature and at 3 bar hydrogen pressure until no further uptake of hydrogen is discernible. The catalyst is filtered off and rinsed with 13.3 l methanol. 60 l of methanol are distilled off under a weak vacuum. If there is no crystal formation, the distillation residue is inoculated. Then at 50° C. 30 l i-of propanol are metered in and within 1 hour the mixture is cooled to 0° C. At 0° C. it is stirred for 1 hour, suction filtered and washed with 15 l cold i-propanol. The moist product is dissolved in 50 liters of methanol. The resulting solution is filtered clear and the pressure filter is rinsed with 10 liters of methanol. Then 52 l methanol are distilled off under a weak vacuum (about 500 mbar). If there is no crystal formation, the distillation residue is inoculated. Then 22.6 l i-propanol are metered in. The mixture is cooled to 0° C., and the suspension is stirred for 1 hour at 0° C. The suspension is suction filtered, washed with 15 liters of cold i-propanol and dried in vacuo at 50° C. Yield (1): 63-70%.


1-[2-hydroxy-5-(phenylmethoxy)-phenyl]-ethanone: 20 kg (131.4 mol) 2-acetyl-hydroquinone 6a are dissolved in 150 l methylisobutylketone and combined with 19.98 kg (144.6 mol) potassium carbonate. At 60° C., 22.48 kg (131.5 mol) benzyl bromide are added. The reaction mixture is stirred for 20 hours at 60° C. The reaction mixture is cooled to 25° C. and the solid is filtered off. The filtrate is washed twice with a solution of 0.96 kg (11.8 mol) sodium hydroxide solution (50%) and 60 l water at 25° C. The methylisobutylketone is largely distilled off in vacuo, and the residue is dissolved in 80 l methanol at 60° C. The solution is cooled to 0° C. and stirred for 1 hour at this temperature to complete the crystallisation.


Yield (5a): 24.07 kg (75.6%), chemical purity according to HPLC: 99.2%.


1-[2-hydroxy-3-nitro-5-(phenylmethoxy)-phenyl]-ethanone: 10.00 kg (41.27 mol) 1-[2-hydroxy-5-(phenylmethoxy)-phenyl]-ethanone 5a are dissolved in 50 l acetic acid. 4.40 kg (45.40 mol) nitric acid 65% are metered into this solution at 15 to 20° C. The feed vessel is rinsed with 4 l acetic acid. The reaction mixture is stirred for 1 hour. After inoculation 50 l water are added. The suspension obtained is stirred for 1 hour at 10° C. to complete the crystallisation. The product is centrifuged and dried at 50° C.


Yield (4a): 10.34 kg (87.2%), chemical purity according to HPLC: 99.0%.


8-acetyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one: 15.00 kg (52.22 mol) 1-[2-hydroxy-3-nitro-5-(phenylmethoxy)-phenyl]-ethanone 4a, 0.165 kg platinum (IV) oxide and 45 l 2-methyltetrahydrofuran are hydrogenated at 3 bar hydrogen pressure and an internal temperature of 25° C. until no further hydrogen uptake is discernible. The catalyst is filtered off and washed with 20 l of 2-methyltetrahydrofuran. 23.09 kg (167.09 mol) potassium carbonate are placed in another reactor, and the reaction mixture from the first reactor is added. It is rinsed with 22 l of 2-methyltetrahydrofuran. Then within 30 minutes 9.44 kg (83.55 mol) chloroacetyl chloride are metered into the suspension. After 2.5 hours reaction time at 65° C., 101 l water are added. The aqueous phase is separated off at 55° C. Then 34 l 2-methyltetrahydrofuran are distilled off from the organic phase in vacuo. After heating to reflux temperature, 180 l methylcyclohexane are metered in within 30 minutes at reflux temperature. The suspension obtained is cooled to 20° C. and stirred for another 1 hour at this temperature to complete the crystallisation. Then the precipitate is removed by centrifuging, washed with 113 l methylcyclohexane and dried at 50° C.


Yield (3a): 12.70 kg (81.8%), chemical purity according to HPLC: 98.4%.


8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one: 12.00 kg (40.36 mol) 8-acetyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 3a are dissolved in 108 l 1,4-dioxane. Then a solution of 24.33 kg (50.45 mol) tetrabutylammonium tribromide in 48 l of 1,4-dioxane and 12 l methanol is metered into the suspension at 20° C. The reactor contents are stirred for 2 hours at 20° C. Then 72 l water are added at 20° C. within 15 minutes. After cooling to 3° C. the mixture is stirred for 1 hour, centrifuged and washed with a mixture of 9 l of 1,4-dioxane and 4.5 l water. Then it is washed with 60 l water and dried in vacuo at 50° C.


Yield (2a): 11.29 kg (74.4%), chemical purity according to HPLC: 98.0%.


8-(2R)-Oxiranyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one: 12.00 kg (31.90 mol) 8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 2a are dissolved in 180 l tetrahydrofuran and cooled to −30° C. 63 kg (70.18 mol) (−)-DIP chloride in hexane 65% are metered in within 1.5 hours. The reaction mixture is stirred for 1 hour and heated to 0° C. At this temperature 11.48 kg (143.54 mol) sodium hydroxide solution (50%), mixed with 36 l water, are metered in. Then the feed vessel is rinsed with 9 l water. The pH value at the end of the addition should be 13. The mixture is heated to 20° C. and stirred for 1 hour. A mixture of 4.5 l (42.11 mol) industrial grade hydrochloric acid (30%) and 18.6 l water is metered in until a pH of 8.5 is achieved. After the addition of 84 l of ethyl acetate the mixture is heated to 30° C. After phase separation half the solvent is distilled off from the organic phase, the residue is combined with 120 l tert-butyl-methylether, cooled to 0° C. and stirred for 1 hour. The product is isolated, washed with tert-butylmethylether and dried in vacuo at 50° C.


Yield (1a): 8.06 kg (85.0%), purity of enantiomers according to HPLC: 98.3%.


Compounds of formula 3b: 24.68 kg (72.6 mol) methylmagnesium chloride (22% solution in THF) are dissolved in 35 l toluene and cooled to 16° C. At 16-22° C. a solution of 60.9 mol arylacetone of formula 4b and 10 l toluene is metered in and the mixture is stirred at 22° C. for 1 hour. The reaction solution is metered into a mixture of 45 l water and 5.22 kg (51.1 mol) sulphuric acid at a temperature of 2-17° C. The two-phase mixture is stirred, and the aqueous phase is separated off. The organic phase is washed with a solution of 1.00 kg (11.9 mol) sodium hydrogen carbonate and 11 l water. The solvent is dissolved off completely in vacuo. The residue is dissolved in 65.5 l of n-heptane. After cooling to 2° C. the reaction mixture is stirred for 3 hours at this temperature. Then the product is isolated, washed with 17.5 l of n-heptane and dried in vacuo at 25° C.


Yield (3b): 75-80%, chemical purity according to HPLC: 98.9-99.9%.


Compounds of formula 2b: 55.48 mol of 1-aryl-2-methyl-propan-2-ol of formula 3b are placed in 6.83 kg (166.44 mol) acetonitrile and 13 l acetic acid and heated to 40° C. 5.66 kg (55.48 mol) sulphuric acid are metered in at 50-55° C. Then the mixture is stirred for 3 hours at 50° C. In a second reactor 160 l water, 20 l tert-butylmethylether and 21 l methylcyclohexane are cooled to 10° C. The contents of the first reactor are transferred into the second reactor. The pH of the reactor contents is adjusted to 9.5 with about 40 l of ammonia solution (25%). The suspension is cooled to 5° C. and stirred for 1 hour at this temperature. The product is separated by centrifuging and washed with 30 l water as well as with a mixture of 7.5 l tert-butylmethylether and 7.5 l methylcyclohexane. The damp product is heated to 75° C. in 25 l ethanol (96%) and at this temperature combined with 30 l water. The solution is stirred for 15 minutes at 85° C., then cooled to 2° C. and stirred for 1 hour at this temperature. The product is isolated, washed with a mixture of 5 l water and 5 l ethanol (96%) and dried.


Yield (2b): 65-71%, chemical purity according to HPLC: 98.6-99.8%.


Compounds of formula 1b: A mixture of 45.2 mol N-[2-aryl-1,1-dimethyl-ethyl]-acetamide of formula 2b, 12.07 kg KOH (180.8 mol), 15 l ethoxyethanol and 15 l ethyleneglycol is heated to 150° C. for 12 hours. After cooling to ambient temperature the mixture is diluted with 61 l water and 31 l toluene. The phases are separated and the organic phase is washed once more with 30 l water. The organic phase is combined with 52 l water. It is acidified with 8.91 kg hydrochloric acid (90.4 mol). After phase separation the aqueous product phase is combined with 30 l toluene and made alkaline with 9.04 kg 50% NaOH (113.0 mol). After phase separation the organic product phase is evaporated down in vacuo to leave an oily residue.


Yield (1b): 69-75%, chemical purity according to HPLC: 94-96%.


In the methods described above for synthesising the compounds of formulae 3b, 2b and 1b the groups R1, R2 and R3 may have the following meanings, for example:

















R1
R2
R3





















Example 1
H
H
OMe



Example 2
2-F
H
F



Example 3
3-F
5-F
H



Example 4
H
H
OEt



Example 5
H
H
F










Analogously to the preparation methods described hereinbefore it is thus possible to obtain the R-forms of the following compounds of formula 1:

  • 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one;
  • 8-{2-[2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
  • 8-{2-[2-(3,5-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
  • 8-{2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
  • 8-{2-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one.

Claims
  • 1. A process for preparing a compound of formula 1,
  • 2. A process according to claim 1, said process further comprising reacting a compound of formula 3a,
  • 3. A process according to claim 1, said process further comprising reacting a compound of formula 2b with a strong base in an organic solvent,
  • 4. A process according to claim 3, said process further comprising reacting a compound of formula 3b with acetonitrile in the presence of an acid in an organic solvent,
  • 5. A process according to claim 4, said process further comprising reacting in an organic solvent a compound of formula 4b with methylmagnesium bromide or methylmagnesium chloride,
Priority Claims (1)
Number Date Country Kind
05107470 Aug 2005 EP regional
Parent Case Info

This application is a continuation application of U.S. application Ser. No. 11/463,703, filed Aug. 10, 2006, now abandoned, which claims the benefit of European Patent Application EP 05107470, filed Aug. 15, 2005, the contents of which are incorporated herein in their entireties.

US Referenced Citations (128)
Number Name Date Kind
4215119 Mentrup et al. Jul 1980 A
4252951 Jackson et al. Feb 1981 A
4460581 Schromm et al. Jul 1984 A
4570630 Elliott et al. Feb 1986 A
4656168 Atkinson et al. Apr 1987 A
5035237 Newell et al. Jul 1991 A
5223614 Schromm et al. Jun 1993 A
5472143 Bartels et al. Dec 1995 A
5497944 Weston et al. Mar 1996 A
5502078 Holloway et al. Mar 1996 A
5750701 Beeley et al. May 1998 A
5753417 Ulrich May 1998 A
5911851 Bartels et al. Jun 1999 A
5947118 Hochrainer et al. Sep 1999 A
5955058 Jager et al. Sep 1999 A
5964416 Jaeger et al. Oct 1999 A
5998430 Schwantes et al. Dec 1999 A
6007676 Bartels et al. Dec 1999 A
6176442 Eicher et al. Jan 2001 B1
6453795 Eicher et al. Sep 2002 B1
6491897 Freund et al. Dec 2002 B1
6503362 Bartels et al. Jan 2003 B1
6582678 Staniforth Jun 2003 B2
6706726 Meissner et al. Mar 2004 B2
6747154 Brandenburg et al. Jun 2004 B2
6846413 Kadel et al. Jan 2005 B1
6905239 Boeck et al. Jun 2005 B2
6951888 Buettner et al. Oct 2005 B2
7056916 Konetzki et al. Jun 2006 B2
7084153 Banholzer et al. Aug 2006 B2
7135500 Konetzki et al. Nov 2006 B2
7160882 Bouyssou et al. Jan 2007 B2
7220742 Lustenberger et al. May 2007 B2
7244728 Bouyssou et al. Jul 2007 B2
7244742 Pieper et al. Jul 2007 B2
7273603 Schmidt Sep 2007 B2
7307076 Konetzki et al. Dec 2007 B2
7332175 Konetzki Feb 2008 B2
7375104 Bouyssou et al. May 2008 B2
7417051 Banholzer et al. Aug 2008 B2
7423036 Konetzki et al. Sep 2008 B2
7429583 Bouyssou et al. Sep 2008 B2
7491719 Lustenberger et al. Feb 2009 B2
7727984 Konetzki et al. Jun 2010 B2
7786111 Konetzki et al. Aug 2010 B2
8034809 Lustenberger et al. Oct 2011 B2
8044046 Konetzki et al. Oct 2011 B2
20010008632 Freund et al. Jul 2001 A1
20020002262 Bier Jan 2002 A1
20020022625 Walland et al. Feb 2002 A1
20020091115 Dyatkin et al. Jul 2002 A1
20020115680 Meissner et al. Aug 2002 A1
20020119991 Meissner et al. Aug 2002 A1
20020189610 Bozung et al. Dec 2002 A1
20030018019 Meade et al. Jan 2003 A1
20030043687 Boeck et al. Mar 2003 A1
20030119859 Gavin Jun 2003 A1
20030152523 Martin et al. Aug 2003 A1
20030207912 Eickmeier et al. Nov 2003 A1
20040002502 Banholzer et al. Jan 2004 A1
20040010003 Banholzer et al. Jan 2004 A1
20040024007 Pairet et al. Feb 2004 A1
20040044020 Meade et al. Mar 2004 A1
20040048886 Meade et al. Mar 2004 A1
20040048887 Meade et al. Mar 2004 A1
20040058950 Meade et al. Mar 2004 A1
20040087617 Meissner et al. May 2004 A1
20040121996 Barvian et al. Jun 2004 A1
20040122108 Buettner et al. Jun 2004 A1
20040132759 Konetzki et al. Jul 2004 A1
20040138307 Konetzki et al. Jul 2004 A1
20040147513 Konetzki et al. Jul 2004 A1
20040166065 Schmidt Aug 2004 A1
20040228805 Pieper et al. Nov 2004 A1
20050004228 Konetzki Jan 2005 A1
20050008578 Schmidt Jan 2005 A1
20050025718 Meade et al. Feb 2005 A1
20050026948 Meade et al. Feb 2005 A1
20050101625 Boeck et al. May 2005 A1
20050137242 Walland et al. Jun 2005 A1
20050154006 Meade et al. Jul 2005 A1
20050165013 Meade et al. Jul 2005 A1
20050186175 Meade et al. Aug 2005 A1
20050222144 Konetzki et al. Oct 2005 A1
20050239778 Konetzki et al. Oct 2005 A1
20050255050 Trunk et al. Nov 2005 A1
20050256114 Grauert et al. Nov 2005 A1
20050256115 Aven Nov 2005 A1
20050267106 Lustenberger et al. Dec 2005 A1
20050272726 Konetzki et al. Dec 2005 A1
20060003268 Hong et al. Jan 2006 A1
20060057074 Meade et al. Mar 2006 A1
20060063817 Bouyssou et al. Mar 2006 A1
20060106213 Konetzki et al. May 2006 A1
20060116398 Mammen et al. Jun 2006 A1
20060189607 Konetzki et al. Aug 2006 A1
20060222598 Schmidt Oct 2006 A1
20070027148 Lustenberger et al. Feb 2007 A1
20070066609 Bouyssou et al. Mar 2007 A1
20070086957 Bouyssou et al. Apr 2007 A1
20070088030 Niklaus-Humke et al. Apr 2007 A1
20070088160 Krueger et al. Apr 2007 A1
20070148598 Colburn et al. Jun 2007 A1
20070155741 Konetzki et al. Jul 2007 A1
20080041369 Radau et al. Feb 2008 A1
20080041370 Radau et al. Feb 2008 A1
20080063608 Pieper et al. Mar 2008 A1
20080167298 Konetzki et al. Jul 2008 A1
20080280897 Aven Nov 2008 A1
20080293710 Aven Nov 2008 A1
20090088408 Meade et al. Apr 2009 A1
20090092558 Konetzki et al. Apr 2009 A1
20090099225 Freund et al. Apr 2009 A1
20090137578 Lustenberger et al. May 2009 A1
20090155185 Meade et al. Jun 2009 A1
20090181961 Konetzki et al. Jul 2009 A1
20090185983 Freund et al. Jul 2009 A1
20100009984 Niklaus-Humke et al. Jan 2010 A1
20100022770 Rodriguez Dehli et al. Jan 2010 A1
20100331288 Aven et al. Dec 2010 A1
20110135582 Bouyssou et al. Jun 2011 A1
20110190284 Niklaus-Humke et al. Aug 2011 A1
20110281858 Aven Nov 2011 A1
20110319402 Heblich Dec 2011 A1
20120034275 Trunk et al. Feb 2012 A1
20120035169 Aven Feb 2012 A1
20120058980 Radau et al. Mar 2012 A1
20120263655 Bouyssou et al. Oct 2012 A1
Foreign Referenced Citations (94)
Number Date Country
1180012 Dec 1984 CA
2164222 Dec 1994 CA
2225601 Jan 1997 CA
2232151 Apr 1997 CA
2233981 Apr 1997 CA
2237853 Jun 1997 CA
2275392 Jul 1998 CA
2300908 Apr 1999 CA
2405745 Nov 2001 CA
2450961 Jan 2003 CA
2455167 Jan 2003 CA
2454935 Feb 2003 CA
2425539 Apr 2003 CA
2425557 Apr 2003 CA
2471578 Aug 2003 CA
2479652 Sep 2003 CA
2481876 Oct 2003 CA
2492037 Jan 2004 CA
2495454 Mar 2004 CA
2501055 Apr 2004 CA
2506082 Jun 2004 CA
2506109 Jun 2004 CA
2558067 Oct 2005 CA
2559699 Nov 2005 CA
2559700 Nov 2005 CA
2562859 Nov 2005 CA
2564379 Nov 2005 CA
2565915 Nov 2005 CA
2624584 Apr 2007 CA
2624786 Apr 2007 CA
2660480 Feb 2008 CA
2660488 Feb 2008 CA
2675094 Jul 2008 CA
2738616 May 2010 CA
2738617 May 2011 CA
1144713 Mar 1963 DE
3625685 Mar 1987 DE
102004019540 Nov 2005 DE
102004024454 Dec 2005 DE
0072505 Mar 1983 EP
0073505 Mar 1983 EP
0237507 Sep 1987 EP
0321864 Jun 1989 EP
2106102 Apr 1983 GB
09-012518 Jan 1997 JP
11-255743 Sep 1999 JP
9114468 Oct 1991 WO
9407607 Apr 1994 WO
9428958 Dec 1994 WO
9701329 Jan 1997 WO
9712683 Apr 1997 WO
9712687 Apr 1997 WO
9720590 Jun 1997 WO
9827959 Jul 1998 WO
9916530 Apr 1999 WO
0158425 Aug 2001 WO
0183462 Nov 2001 WO
0230928 Apr 2002 WO
0232899 Apr 2002 WO
02080884 Oct 2002 WO
03000241 Jan 2003 WO
03000265 Jan 2003 WO
03011810 Feb 2003 WO
03017970 Mar 2003 WO
03064417 Aug 2003 WO
03078429 Sep 2003 WO
03084502 Oct 2003 WO
2004000840 Dec 2003 WO
2004004775 Jan 2004 WO
2004022058 Mar 2004 WO
2004033412 Apr 2004 WO
2004045618 Jun 2004 WO
2004046083 Jun 2004 WO
2004087142 Oct 2004 WO
2005014044 Feb 2005 WO
2005092870 Oct 2005 WO
2005102349 Nov 2005 WO
2005111005 Nov 2005 WO
2005102350 Nov 2005 WO
2005110359 Nov 2005 WO
2005110421 Nov 2005 WO
2007020227 Feb 2007 WO
2007042153 Apr 2007 WO
2007042467 Apr 2007 WO
2007042468 Apr 2007 WO
2007054498 May 2007 WO
2007148806 Dec 2007 WO
2008020056 Feb 2008 WO
2008020057 Feb 2008 WO
2008024045 Feb 2008 WO
2008090193 Jul 2008 WO
2009059893 May 2009 WO
2010057927 May 2010 WO
2010057928 May 2010 WO
Non-Patent Literature Citations (119)
Entry
Armarego, W. L. F.; Purification of Laboratory Chemicals (4th Edition); (1997) p. 529; Elsevier Publisher.
Babin, D. et al; A Biomimetic Synthesis of Chrysanthemol; (1981) vol. 37. No. 2 pp. 325-332.
Balzano, G. et al; “Effectiveness and Acceptability of a Domiciliary Multidrug Inhalation Treatment in Elderly Patients with Chronic Airflow Obstruction: Metered Dose Inhaler Versus Jet Nebulizer”; J. of Aerosol Medicine (2000) vol. 13, No. 1, 2000, pp. 25-33.
Bedi, Rajinder Singh; Inhaled Corticosteroids in COPD; Indian Journal Chest Dis Allied Sci (2005) vol. 47, pp. 243-244.
Bernstein, J; Controlling the Polymorphic Form Obtained; Polymorphism in Molecular Crystals in Chapter 3; Clarendon Press, Oxford, 2002, pp. 66-93.
Bernstein, J; Analytical Techniques for Studying and Characterizing Polymorphs; Analytical Techniques for Studying and Characterizing Polymorphs; Polymorphism in Molecular Crystals in Chapter 4; Clarendon Press, Oxford, 2002, pp. 94-150.
Brittain, Harry G., et al; Physical Characterization of Pharmaceutical Solids; Pharmaceutical Research (1991) vol. 8, pp. 963-973.
Brittain, Harry G., et al; Overview of Physical Characterization Methodology; Physical Characterization of Pharmaceutical Solids in Chapter 1; Marcel Dekker, New York, 1995, pp. 1-35.
Brittain, Harry G; Methods for the Characterization of Polymorphs and Solvates in Chapter 6; Polymorphism in Pharmaceutical Solids; Marcel Dekker, New York, 1999, pp. 227-278.
Brittain, Harry G; Solid State Analysis; Handbook of Modern Pharmaceutical Analysis in Chapter 3; Marcel Dekker, New York, 2001, pp. 57-84.
Brittain, Harry G; Preparation and identification of Polymorphs and Solvatomorphs; Preformulation in Solid Dosage Form Development; Informa Healthcare Press, New York, 2008, pp. 185-228.
Bugay, David E; Characterization of the Solid-State: Spectroscopic Techniques; Advanced Drug Delivery Reviews (2001) vol. 48, pp. 43-65.
Buu-Hoi, N. P. et al; Alpha, Alpha-Dimethyl-Beta-Arylethymanines, and Their Behavior in the Bischler-Napieralski Reaction; Journal of Organic Chemistry (1958) vol. 23, No. 1 pp. 42-45.
Chronic Obstructive Pulmonary Disease (Wikepedia) Jul. 3, 2008.
Crapo, James D., et al; Beta-Adrenergic Receptor Agonists; Baum's Textbook of Pulmonary Disease; 7th Edition (2004) Lippincott Williams & Wilkins.
Declaration of Dr. Andreas Schnapp Under 37 C.F.R. § 1.132 submitted in U.S. Appl. No. 11/109,030, filed Apr. 19, 2005.
Dutu, S. et al; Lung Function in COPD Patients Under Long Term Inhaled Therapy With Bronchodilator Agents and Beclometasone, European Respiratory Journal, (1997) Supp., Bd. 10, Nr. 25, Supp. 20.
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
GINA: Global Initiative for Asthma: Pocket Guide for Asthma Management and Prevention (2005) 30 pages.
Griesser, Ulrich J.; The Importance of Solvates; Polymorphism: in the Pharmaceutical Industry (2006) chapter 8; pp. 211-233.
Guillory, J, Keith; Generation of Polymorphs, Hydrates, Solvated, and Amorphous Solids; Marcel Dekker, New York, 1999, pp. 183-226.
Hamada, Takayuki et al; Practical Synthesis of Optically Active Styrene Oxides Via reductive Transformation of 2-Chloroacetophenones with Chiral Rhodium Catalysts; Organic Letters (2002) vol. 4 No. 24 pp. 4373-4376.
Hilfiker, Rolf et al; Polymorphism—Integrated Approach from High-Throughput Screening to Crystallization Optimization; Journal of Thermal Analysis and Calorimetry (2003) vol. 73, pp. 429-440.
Hilfiker, Rolf et al; Approaches to Polymorphism Screening; Polymorphism in the Pharmaceutical Industry in Chapter 11; Wiley-VCH, Mannheim, 2006, pp. 287-308.
Jackson, Catherine M. et al; Benefit-Risk Assessment of Long-Acting B2-Agonists in Asthma; Drug Safety 2004 vol. 27 No. 4 pp. 243-270.
Klimanskaya, E.V.; Chronic Obstructive Lung Diseases in Children; http://www.nedug.ru/lib/lit/therap/01oct/therap204/therap.htm (2008) pp. 1-5.
Martinez, Fernando J. et al; Is It Astham or COPD? Postgraduate Medicine Online (2005) vol. 117, No. 3, pp. 1-13.
Merck Manual Home Edition; Respiratory Distress Syndrome; Acidosis; Pneumococcal Infections; Lung Cancer and Severe Acute Respiratory Syndrome (SARS); retrieved Jun. 10, 2007.
Morissette, Sherry L., et al; High-Throughput Crystallization: Polymorphs, Salts, Co-Crystals and Solvates of Pharmaceutical Solids; Advanced Drug Delivery Reviews (2004) vol. 56, pp. 275-300.
Newman, Ann W., et al; Form Selection of Pharmaceutical Compounds; Handbook of Pharmaceutical Analysis in Chapter 1; Marcel Dekker; New York, 2001, pp. 1-57.
O'Byrne, Paul M. et al; Inhaled Beta 2-Agonists in the Treatment of Asthma; The New England Journal of Medicine (1996) vol. 335 No. 12 pp. 886-888.
Sovani, Milind P. et al; A Benefit-Risk Assessment of Inhaled Long-Acting B2-Agonists in the Management of Obstructive Pulmonary Disease; Drug Safety 2004 vol. 27 No. 10 pp. 689-715.
Storey, PD.D, Richard A., et al; Integration of High Throughput Screening Methodologies and Manual Processes for Solid Form Selection; American Pharmaceutical Review (2003) pp. 100-105.
Threlfall, Terence L; Analysis of Organic Polymorphs: A Review; Analyst (1995) vol. 120, pp. 2435-2460.
Timberlake, Jack W. et al; Thiadiaziridine 1,1-Dioxides: Synthesis and Chemistry; Journal of Organic Chemistry (1981) vol. 46, No. 10 pp. 2082-2089; American Chemical Society.
Ukena, D.; Ciclesonide—A New Inhaled Corticosteroid. Pharmacological Properties and Clinical Efficacy in the Treatment of Asthma; Pneumalogie (2005) vol. 59 pp. 689-695.
Waldeck, Bertil; Beta-Adrenoceptor Agonists and Asthma—100 Years of Development; European Journal of Pharmacology (2002) vol. 445 pp. 1-12.
www.betterhealthcenter.com/allergy-asthma.htm: pp. 1 or 4 and 2 of 4; retrieved Mar. 26, 2006.
Yasuda, Masahide et al; Redox-Photosensitized Aminations of 1,2-Benso-1,3-Cycloalkadienes, Arylcyclopropanes, and Quadricyclane with Ammonia; Journal of Organic Chemistry (2003) vol. 68, No. 20 pp. 7618-7624; American Chemistry Society.
Vippagunta, Sudha R. et al; Crystalline Solids; Advanced Delivery Reviews (2001) vol. 48, pp. 3-26.
International Search Report for PCT/EP03/12565 mailed on Aug. 4, 2004.
International Search Report for PCT/EP2005/004073 mailed on Aug. 3, 2005.
International Search Report for PCT/EP2005/004075 mailed on Aug. 3, 2005.
International Search Report for PCT/EP2005/005028 mailed on Jan. 24, 2006.
International Search Report for PCT/EP2005/005078 mailed on Oct. 28, 2005.
International Search Report for PCT/EP2005/005079 mailed on Aug. 8, 2005.
International Search Report for PCT/EP2006/067126 mailed on Jun. 4, 2007.
International Search Report PCT/EP2006/065217 mailed on Nov. 22, 2006.
International Search Report PCT/EP2006/067122 mailed on Feb. 12, 2007.
International Patent Application PCT/EP2008/064201 filed under the PCT on Oct. 21, 2008.
Non-Final Office Action dated Feb. 25, 2005 from U.S. Appl. No. 10/705,012, filed Nov. 10, 2003.
Non-Final Office Action dated Jun. 21, 2005 from U.S. Appl. No. 10/705,012, filed Nov. 10, 2003.
Notice of Allowability dated Dec. 12, 2005 from U.S. Appl. No. 10/705,012, filed Nov. 10, 2003, now U.S. Patent No. 7,056,816.
Final Office Action dated Mar. 8, 2007 from U.S. Appl. No. 11/109,030, filed Apr. 19, 2005.
Non-Final Office Action dated Nov. 29, 2007 from U.S. Appl. No. 11/109,030, filed Apr. 19, 2005.
Non-Final Office Action dated Sep. 22, 2008 from U.S. Appl. No. 11/109,030, filed Apr. 19, 2005.
Office Action dated Apr. 18, 2007 from U.S. Appl. No. 11/125,756, filed May 10, 2005.
Final Office Action dated Dec. 18, 2007 from U.S. Appl. No. 11/125,756, filed May 10, 2005.
Non-Final Office Action dated Sep. 28, 2006 from U.S. Appl. No. 11/125,890, filed May 10, 2005.
Final Office Action dated Mar. 1, 2007 from U.S. Appl. No. 11/125,890, filed May 10, 2005.
Non-Final Office Action dated Dec. 28, 2005 from U.S. Appl. No. 11/128,032, filed May 12, 2005.
Non-Final Office Action dated Nov. 21, 2006 from U.S. Appl. No. 11/128,032, filed May 12, 2005.
Office Action dated Jun. 14, 2007 from U.S. Appl. No. 11/128,141, filed May 12, 2005.
Response to Office Action dated Dec. 12, 2007 from U.S. Appl. No. 11/128,141, filed May 12, 2005.
Response to Office Action filed Dec. 12, 2007 from U.S. Appl. No. 11/128,141, filed May 12, 2005.
Non-Final Office Action dated Mar. 24, 2008 from U.S. Appl. No. 11/128,141, filed May 12, 2005.
Office Action dated Apr. 25, 2008 from U.S. Appl. No. 11/132,075, filed May 18, 2005.
Non-Final Office Action dated Jul. 17, 2007 from U.S. Appl. No. 11/222,149, filed Sep. 8, 2005.
Non-Final Office Action dated Mar. 20, 2006 from U.S. Appl. No. 11/275,730, filed Jan. 26, 2006.
Final Office Action dated Oct. 23, 2006 from U.S. Appl. No. 11/275,730, filed Jan. 26, 2006.
Non-Final Office Action dated Mar. 28, 2008 from U.S. Appl. No. 11/543,168, filed Oct. 4, 2006.
Non-Final Office Action dated Apr. 4, 2008 U.S. Appl. No. 11/543,477, filed Oct. 5, 2006.
Non-Final Office Action dated Apr. 3, 2008 U.S. Appl. No. 11/543,694, filed Oct. 5, 2006.
Non-Final Office Action dated Jun. 4, 2007 from U.S. Appl. No. 11/600,417, filed Nov. 15, 2006.
Office Action dated May 24, 2007 from U.S. Appl. No. 11/677,112, filed Feb. 21, 2007.
Non-Final Office Action dated Apr. 30, 2008 from U.S. Appl. No. 11/677,112, filed Feb. 21, 2007.
Office Action dated Apr. 28, 2008 from U.S. Appl. No. 12/036,618, filed Feb. 25, 2008.
Non-Final Office Action dated Jan. 3, 2006 from U.S. Patent No. 7,160,882 B2.
Non-Final Office Action dated Jun. 5, 2006 from U.S. Patent No. 7,160,882 B2.
U.S. Appl. No. 11/676,823, filed Feb. 20, 2007.
U.S. Appl. No. 12/093,026, filed May 8, 2008.
U.S. Appl. No. 12/036,618, filed Feb. 25, 2008.
U.S. Appl. No. 12/133,066, filed Jun. 4, 2008.
Bouyssou, T. et al. “Discovery of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist with a 24 h Bronchodilatory Efficacy” Bioorganic & Medicinal Chemistry Letters, 20, (2010) pp. 1410-1414.
Bouyssou, T. et al. “Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Flour-Long Duration of Action in Preclinical Models” The Journal of Pharmacology and Experimental Therapeutics, vol. 334 No. 1, (2010) pp. 53-62.
Braga, et al. “Making crystals from crystals: a green route to crystal engineering and polymorphism” ChemComm 2005, 3635-3645.
Buettner, F. et al. “Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions”; U.S. Appl. No. 10/666,068, filed Sep. 19, 2003.
Calvo, G. Mario; Is it useful to add an Anticholinergic Treatment to b2-Adrenergic Medication in Acute Asthma Attach? Invest. Allegorl Clin Immunol (1998) V 8, No. 1 pp. 30-34.
Coutts, Ronald T. et al; Synthesis of Two in Vivo Metabolites of N-(N-Propyl)Phentermine; Canadian Journal of Chemistry (1978) vol. 56 pp. 3054-3058.
Decision from the Board of Patent Appeals and Interferences in Appeal No: 2000-0600. (May 6, 2002).
Declaration of Dr. Harry G. Brittain under 37 C.F.R. x 1.132 submitted in U.S. Appl. No. 11/677,112 on Apr. 1, 20009 and U.S. Appl. No. 11/132,075 on Apr. 3, 2009.
Derwent Publications Ltd. GB, Class B05, Nov. 10, 1998.
EP 05292120.2 US PTO Oct 11, 2005.
Final Office Action dated Jun. 28, 2011 in U.S. Appl. No. 11/109,094, filed Apr. 19, 2005.
Final Office Action dated Mar. 11, 2011 from U.S. Appl. No. 12/407,982, filed Mar. 20, 2009.
GOLD Pocket Guide, Jul. 2003.
GOLD Pocket Guide, Jul. 2004.
International Preliminary Report on Patentability for PCT/EP2007/058518 filed Aug. 16, 2007 and issued Mar. 17, 2009.
International Preliminary Report on Patentability for PCT/EP2007/058518 filed Aug. 16, 2007 and issued Mar. 17, 2009. (English Translation).
International Search Report for PCT/EP2007/058518 filed Aug. 16, 2007 and mailed Oct. 19, 2007.
International Search Report for PCT/EP2009/065406 mailed on Jan. 12, 2010.
International Search Report for PCT/EP2009/065407 mailed on Jan. 20, 2010.
International Search Report PCT/EP2006/068191 mailed Feb. 5, 2007.
International Search Report PCT/EP2008/050800 mailed Aug. 13, 2009.
Lovoilette, et al. “Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma” Am J Respir Crit Care Med 1999, 160:1862-1868.
Nicholson, et al. “Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer” Endocrine-Related Cancer (1999) 6 373-387.
Non-Final Office Action dated Dec. 8, 2010 from U.S. Appl. No. 11/128,141, filed May 12, 2005.
Non-Final Office Action dated Mar. 16, 2011 from U.S. Appl. No. 12/133,066, filed Jun. 4, 2008.
Office Action dated Mar. 18, 2011, in U.S. Appl. No. 12/093,026, filed Jul. 14, 2008.
Schwender, Charles F. et al. “3[a-(tert-Butylamino)methyl]-5-hydroxy-m-xylene-a,a′-diol, a Selective Bronchodilator” Journal of Medicinal Chemistry, (1974) vol. 17, No. 10, pp. 1112-1115.
Seddon, et al. “Pseudopolymorph: A Polemic” American Chemical Society (2004).
Sereda, V.P., et al; Inhalation Therapy of Chronic Obstructive Lung Diseases; www.pharmindex.ru/practic/4—pulmo.html <http://www.pharmindex.ru/practic/4—pulmo.html>. Feb. 2003, pp. 1-35.
Tamura, Yasumitsu et al. “erythro-5[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a Terbutaline-Type Derivative of the Bronchodilator Procaterol” J. Med. Chem. (1981) vol. 24, pp. 634-636.
U.S. Appl. No. 13/332,984, filed Dec. 21 2011, Ingo Konetzki.
West, Anthony R., “Solid State Chemistry and its Applications” Wiley, New York 1988 pp. 358-365.
Wolf, Manfred E; Burger's Medicinal Chemistry, 5ed, Part 1, John Wiley & Sons, (1995) pp. 975-977.
Written Opinion of ISA for PCT/EP2009/065406 mailed on Jan. 12, 2010.
Written Opinion of ISA for PCT/EP2009/065407 mailed on Jan. 20, 2010.
Gould, Philip L. “Salt selection for basic drugs” International Journal of Pharmaceutics (1986) 33, pp. 201-217.
Related Publications (1)
Number Date Country
20110124859 A1 May 2011 US
Continuations (1)
Number Date Country
Parent 11463703 Aug 2006 US
Child 13021946 US